{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:20:33Z","timestamp":1790806833340,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T00:00:00Z","timestamp":1529971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12886-018-0815-1","type":"journal-article","created":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T19:17:19Z","timestamp":1529954239000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab"],"prefix":"10.1186","volume":"18","author":[{"given":"Qizhe","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5045-7899","authenticated-orcid":false,"given":"Hong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,26]]},"reference":[{"key":"815_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.survophthal.2016.12.004","volume":"62","author":"ME Hartnett","year":"2017","unstructured":"Hartnett ME. Advances in understanding and management of retinopathy of prematurity. Surv Ophthalmol. 2017;62:257\u201376.","journal-title":"Surv Ophthalmol"},{"key":"815_CR2","doi-asserted-by":"crossref","unstructured":"American Medical Association. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005;123:991\u20139.","DOI":"10.1001\/archopht.123.7.991"},{"key":"815_CR3","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/00006982-200406000-00006","volume":"24","author":"KH Park","year":"2004","unstructured":"Park KH, Hwang J-M, Choi MY, Yu YS, Chung H. Retinal detachment of regressed retinopathy of prematurity in children aged 2 to 15 years. Retina. 2004;24:368\u201375.","journal-title":"Retina"},{"key":"815_CR4","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1056\/NEJMra1208129","volume":"367","author":"ME Hartnett","year":"2012","unstructured":"Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2012;367:2515\u201326.","journal-title":"N Engl J Med"},{"key":"815_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.siny.2011.08.007","volume":"17","author":"J Lee","year":"2012","unstructured":"Lee J, Dammann O. Perinatal infection, inflammation, and retinopathy of prematurity. Semin Fetal Neonatal Med. 2012;17:26\u20139.","journal-title":"Semin Fetal Neonatal Med"},{"key":"815_CR6","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1136\/bjo.64.10.758","volume":"64","author":"I Ben Sira","year":"1980","unstructured":"Ben Sira I, Nissenkorn I, Grunwald E, Yassur Y. Treatment of acute retrolental fibroplasia by cryopexy. Br J Ophthalmol. 1980;64:758\u201362.","journal-title":"Br J Ophthalmol"},{"key":"815_CR7","doi-asserted-by":"crossref","unstructured":"Casey Eye Institute, Oregon Health Sciences University. Multicenter trial of cryotherapy for retinopathy of prematurity. Snellen visual acuity and structural outcome at 5 1\/2 years after randomization. Arch Ophthalmol. 1996;114:417\u201324.","DOI":"10.1001\/archopht.1996.01100130413008"},{"key":"815_CR8","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1097\/IAE.0000000000000604","volume":"35","author":"A Vinekar","year":"2015","unstructured":"Vinekar A, Jayadev C, Mangalesh S, Kumar AK, Bauer N, Capone AJ, Trese M, Shetty B. Comparing the outcome of single versus multiple session laser photoablation of flat neovascularization in zone 1 aggressive posterior retinopathy of prematurity: a prospective randomized study. Retina. 2015;35:2130\u20136.","journal-title":"Retina"},{"key":"815_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12886-018-0685-6","volume":"18","author":"Z Li","year":"2018","unstructured":"Li Z, Zhang Y, Liao Y, Zeng R, Zeng P, Lan Y. Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP). BMC Ophthalmol. 2018;18:19.","journal-title":"BMC Ophthalmol"},{"key":"815_CR10","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1097\/IAE.0b013e3181ca1457","volume":"30","author":"P Dorta","year":"2010","unstructured":"Dorta P, Kychenthal A. Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin). Retina. 2010;30:S24\u201331.","journal-title":"Retina"},{"key":"815_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12886-015-0001-7","volume":"15","author":"MN Menke","year":"2015","unstructured":"Menke MN, Framme C, Nelle M, Berger MR, Sturm V, Wolf S. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease. BMC Ophthalmol. 2015;15:20.","journal-title":"BMC Ophthalmol"},{"key":"815_CR12","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","volume":"37","author":"W-C Wu","year":"2017","unstructured":"Wu W-C, Shih C-P, Lien R, Wang N-K, Chen Y-P, Chao A-N, Chen K-J, Chen T-L, Hwang Y-S, Lai C-C. Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina. 2017;37:694\u2013701.","journal-title":"Retina"},{"key":"815_CR13","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/eye.2017.18","volume":"31","author":"YJ Ahn","year":"2017","unstructured":"Ahn YJ, Hong KE, Yum HR, Lee JH, Kim KS, Youn YA, Park SH. Characteristic clinical features associated with aggressive posterior retinopathy of prematurity. Eye (Lond). 2017;31:924\u201330.","journal-title":"Eye (Lond)"},{"key":"815_CR14","doi-asserted-by":"crossref","first-page":"102582","DOI":"10.1155\/2015\/102582","volume":"2015","author":"SD Nicoar\u0103","year":"2015","unstructured":"Nicoar\u0103 SD, Nascutzy C, Cristian C, Irimescu I, \u0218tef\u0103nu\u021b AC, Zaharie G, Drugan T. Outcomes and prognostic factors of intravitreal bevacizumab monotherapy in zone i stage 3+ and aggressive posterior retinopathy of prematurity. J Ophthalmol. 2015;2015:102582\u20138.","journal-title":"J Ophthalmol"},{"key":"815_CR15","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s00417-014-2867-0","volume":"253","author":"H Yetik","year":"2015","unstructured":"Yetik H, Gunay M, Sirop S, Salihoglu Z. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey. Graefes Arch Clin Exp Ophthalmol. 2015;253:1677\u201383.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"815_CR16","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.ophtha.2017.03.018","volume":"124","author":"Q Huang","year":"2017","unstructured":"Huang Q, Zhang Q, Fei P, Xu Y, Lyu J, Ji X, Peng J, Li Y-A, Zhao P. Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors. Ophthalmology. 2017;124:1156\u201364.","journal-title":"Ophthalmology"},{"key":"815_CR17","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1097\/IAE.0000000000001685","volume":"38","author":"Y Yonekawa","year":"2018","unstructured":"Yonekawa Y, Wu W-C, Nitulescu CE, Chan RVP, Thanos A, Thomas BJ, Todorich B, Drenser KA, Trese MT, Capone A. Progressive retinal detachment in infants with retinopathy of prematurity treated with intravitreal bevacizumab or ranibizumab. Retina. 2018;38:1079\u201383.","journal-title":"Retina"},{"key":"815_CR18","first-page":"290","volume":"37","author":"J Stone","year":"1996","unstructured":"Stone J, Chan-Ling T, Pe\u2019er J, Itin A, Gnessin H, Keshet E. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 1996;37:290\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"815_CR19","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179\u201382.","journal-title":"Ophthalmology"},{"key":"815_CR20","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855\u20139.","journal-title":"Ophthalmology"},{"key":"815_CR21","first-page":"629","volume":"44","author":"P Fei","year":"2008","unstructured":"Fei P, Zhao P-Q, Chen R-J, Yu Z. Histopathological study of epiretinal membranes in retinopathy of prematurity. Zhonghua Yan Ke Za Zhi. 2008;44:629\u201333.","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"815_CR22","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/bjo.76.9.550","volume":"76","author":"R Walshe","year":"1992","unstructured":"Walshe R, Esser P, Wiedemann P, Heimann K. Proliferative retinal diseases: myofibroblasts cause chronic vitreoretinal traction. Br J Ophthalmol. 1992;76:550\u20132.","journal-title":"Br J Ophthalmol"},{"key":"815_CR23","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1055\/s-2008-1034905","volume":"212","author":"CJ Pournaras","year":"1998","unstructured":"Pournaras CJ, Donati G, Kapetanios AD, Redard M, Bochatay-Piallat ML, Gabbiani G. Myofibroblasts and retinal fibrovascular membranes. Klin Monatsbl Augenheilkd. 1998;212:356\u20138.","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"815_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000223949","volume":"44","author":"KA Drenser","year":"2009","unstructured":"Drenser KA. Anti-angiogenic therapy in the management of retinopathy of prematurity. Dev Ophthalmol. 2009;44:89\u201397.","journal-title":"Dev Ophthalmol"},{"key":"815_CR25","first-page":"41","volume":"43","author":"Y Ikuno","year":"2002","unstructured":"Ikuno Y, Kazlauskas A. TGFbeta1-dependent contraction of fibroblasts is mediated by the PDGFalpha receptor. Invest Ophthalmol Vis Sci. 2002;43:41\u20136.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"815_CR26","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s00417-011-1730-9","volume":"249","author":"K Nassar","year":"2011","unstructured":"Nassar K, Luke J, Luke M, Kamal M, Abd El-Nabi E, Soliman M, Rohrbach M, Grisanti S. The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR). Graefes Arch Clin Exp Ophthalmol. 2011;249:1649\u201360.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"815_CR27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.exer.2014.04.006","volume":"123","author":"K Nassar","year":"2014","unstructured":"Nassar K, Grisanti S, Tura A, Luke J, Luke M, Soliman M, Grisanti S. A TGF-beta receptor 1 inhibitor for prevention of proliferative vitreoretinopathy. Exp Eye Res. 2014;123:72\u201386.","journal-title":"Exp Eye Res"},{"key":"815_CR28","doi-asserted-by":"publisher","first-page":"5798","DOI":"10.4049\/jimmunol.168.11.5798","volume":"168","author":"P Scapini","year":"2002","unstructured":"Scapini P, Nesi L, Morini M, Tanghetti E, Belleri M, Noonan D, Presta M, Albini A, Cassatella MA. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. J Immunol. 2002;168:5798\u2013804.","journal-title":"J Immunol"},{"key":"815_CR29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.bbrc.2007.10.027","volume":"364","author":"S Ai","year":"2007","unstructured":"Ai S, Cheng XW, Inoue A, Nakamura K, Okumura K, Iguchi A, Murohara T, Kuzuya M. Angiogenic activity of bFGF and VEGF suppressed by proteolytic cleavage by neutrophil elastase. Biochem Biophys Res Commun. 2007;364:395\u2013401.","journal-title":"Biochem Biophys Res Commun"},{"key":"815_CR30","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1182\/blood-2015-03-631572","volume":"126","author":"S Massena","year":"2015","unstructured":"Massena S, Christoffersson G, Vagesjo E, Seignez C, Gustafsson K, Binet F, Herrera Hidalgo C, Giraud A, Lomei J, Westrom S, Shibuya M, Claesson-Welsh L, Gerwins P, Welsh M, Kreuger J, Phillipson M. Identification and characterization of VEGF-A-responsive neutrophils expressing CD49d, VEGFR1, and CXCR4 in mice and humans. Blood. 2015;126:2016\u201326.","journal-title":"Blood"},{"key":"815_CR31","first-page":"3115","volume":"31","author":"A Luethy","year":"2011","unstructured":"Luethy A, Stenner F, Lohri C, Muller C, Samaras P, Steiner R, Van den Broek M, Mischo A, Renner C, Knuth A, Ruegg C, Wenger RH, Zweifel M. Autologous stem cell transplantation: leukapheresis product has anti-angiogenic effects in vivo correlating with neutrophil-derived VEGFR1. Anticancer Res. 2011;31:3115\u201324.","journal-title":"Anticancer Res"},{"key":"815_CR32","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171\u201385.","journal-title":"Angiogenesis"},{"key":"815_CR33","doi-asserted-by":"publisher","first-page":"a006502","DOI":"10.1101\/cshperspect.a006502","volume":"2","author":"S Koch","year":"2012","unstructured":"Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med. 2012;2:a006502.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"815_CR34","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/archsurg.134.12.1325","volume":"134","author":"M McCourt","year":"1999","unstructured":"McCourt M, Wang JH, Sookhai S, Redmond HP. Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch Surg. 1999;134:1325\u201331. discussion 1331\u20132","journal-title":"Arch Surg"},{"key":"815_CR35","doi-asserted-by":"publisher","first-page":"5731","DOI":"10.4049\/jimmunol.1203362","volume":"190","author":"K Ganeshan","year":"2013","unstructured":"Ganeshan K, Johnston LK, Bryce PJ. TGF-beta1 limits the onset of innate lung inflammation by promoting mast cell-derived IL-6. J Immunol. 2013;190:5731\u20138.","journal-title":"J Immunol"},{"key":"815_CR36","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/IAE.0b013e3181a68f3a","volume":"29","author":"G Sanghi","year":"2009","unstructured":"Sanghi G, Dogra MR, Das P, Vinekar A, Gupta A, Dutta S. Aggressive posterior retinopathy of prematurity in Asian Indian babies: spectrum of disease and outcome after laser treatment. Retina. 2009;29:1335\u20139.","journal-title":"Retina"},{"key":"815_CR37","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","volume":"123","author":"HA Mintz-Hittner","year":"2016","unstructured":"Mintz-Hittner HA, Geloneck MM, Chuang AZ. Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology. 2016;123:1845\u201355.","journal-title":"Ophthalmology"},{"key":"815_CR38","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1097\/IAE.0b013e31817f2f15","volume":"28","author":"MJ Kim","year":"2008","unstructured":"Kim MJ, Kim S-J, Yu YS. The risk for retinal detachment associated with hemorrhages pre- and postlaser treatment in retinopathy of prematurity. Retina. 2008;28:1451\u20137.","journal-title":"Retina"},{"key":"815_CR39","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ophtha.2016.10.040","volume":"124","author":"E Daniel","year":"2017","unstructured":"Daniel E, Ying GS, Siatkowski RM, Pan W, Smith E, Quinn GE, e-ROP Cooperative Group. Intraocular hemorrhages and retinopathy of prematurity in the telemedicine approaches to evaluating acute-phase retinopathy of prematurity (e-ROP) study. Ophthalmology. 2017;124:374\u201381.","journal-title":"Ophthalmology"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-018-0815-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-018-0815-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-018-0815-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T19:20:48Z","timestamp":1561490448000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-018-0815-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,26]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["815"],"URL":"https:\/\/doi.org\/10.1186\/s12886-018-0815-1","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,26]]},"assertion":[{"value":"7 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was performed in accordance with the principles of the Declaration of Helsinki, 1995 (revised in Edinburgh in 2000). This study was approved by the medical ethics committee of Peking University People\u2019s Hospital. The parents or legal guardians of the patients provided consent for participation in the study on behalf of the underage patients, and written informed consent was obtained.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent for publication of the images was obtained from the patients\u2019 guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"150"}}